FDA approves targeted therapy for KRAS lung cancer mutation

U.S – The Food and Drug Administration has approved a targeted therapy drug by AMGEN INC for non-small cell lung cancer with a specific mutation in a gene known as KRAS. The drug, sotorasib, which will be sold under the brand name Lumakras, shrank tumours with the KRAS mutation in around 36 percent of patients in clinical trials. This medication is designed to target a gene mutation known as KRAS G12C that occurs in about 13 percent of non-small cell lung cancers, or NSCLC, the most common type of lung…

Read More